(2)
ANN ARBOR, MI / ACCESSWIRE / December 18, 2020 / ENDRA Life Sciences Inc. ( ENDRA ) (NASDAQ:NDRA), a developer of enhanced ultrasound technologies, today reported the closing of its previously announced underwritten public offering of 7,143,000 shares of common stock at an offering price of $0.70 per share. In connection with the offering, the underwriter exercised its over-allotment option to purchase an additional 714,286 shares of common stock at the public offering price, less the underwriting discount, in full. As a result, the total offering size was 7,857,286 shares, and the gross proceeds from the offering were $5,500,100, before deducting underwriting discounts and estimated offering expenses. All of the shares of common stock were offered by ENDRA.
ENDRA Life Sciences Announces Pricing of Public Offering of Common Stock
albuquerqueexpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from albuquerqueexpress.com Daily Mail and Mail on Sunday newspapers.
ENDRA Life Sciences : Announces Pricing of Public Offering of Common Stock
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
ENDRA Life Sciences Inc.: ENDRA Life Sciences Announces Pricing of Public Offering of Common Stock
ANN ARBOR, MI / ACCESSWIRE / December 15, 2020 / ENDRA Life Sciences Inc. ( ENDRA ) (NASDAQ:NDRA), a developer of enhanced ultrasound technologies, today announced the pricing of an underwritten public offering of 7,143,000 shares of common stock at an offering price of $0.70 per Common Share. In addition, ENDRA has granted the underwriter a 45-day option to purchase up to an additional 714,286 shares to cover over-allotments, if any. All of the shares are being offered by ENDRA.
ENDRA expects to receive gross proceeds from the offering of $5.0 million prior to deducting underwriting discounts, commissions and other offering expenses. If the underwriter exercises its over-allotment option in full, the gross proceeds would be approximately $5.5 million. The offering is expected to close on December 18, 2020, subject to the satisfaction of customary closing conditions.